EU regulators back Novo Nordisk's (NVO.US) Wegovy for obesity-related heart disease
Friday, Sep 20, 2024 4:10 am ET
NVO --
Danish pharmaceutical company Novo Nordisk (NVO.US) said on Thursday that the European Medicines Agency (EMA) has supported the use of its blockbuster drug Wegovy to treat heart failure in patients with obesity, marking the second time the regulator has supported the use of the drug for an indication beyond weight loss and further strengthening Novo Nordisk's case for multiple health benefits.